The risk of lower gastrointestinal bleeding in low‐dose aspirin users

Summary Background Aspirin increases the risk of gastrointestinal bleeding. Aim To investigate the risk of lower gastrointestinal bleeding (LGIB) in aspirin users. Methods Low‐dose (75‐325 mg daily) aspirin users and controls matched by age, gender and enrollment time in a 1:5 ratio were selected fr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 2017-06, Vol.45 (12), p.1542-1550
Hauptverfasser: Chen, W.‐C., Lin, K.‐H., Huang, Y.‐T., Tsai, T.‐J., Sun, W.‐C., Chuah, S.‐K., Wu, D.‐C., Hsu, P.‐I.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Background Aspirin increases the risk of gastrointestinal bleeding. Aim To investigate the risk of lower gastrointestinal bleeding (LGIB) in aspirin users. Methods Low‐dose (75‐325 mg daily) aspirin users and controls matched by age, gender and enrollment time in a 1:5 ratio were selected from 1 million randomly sampled subjects in the National Health Insurance Research Database of Taiwan. Cox proportional hazard regression models were developed to evaluate the predictors of LGIB with adjustments for age, gender, comorbidities including coronary artery disease, ischaemic stroke, diabetes, hypertension, chronic kidney disease, liver cirrhosis, chronic obstructive pulmonary disease, dyslipidemia, uncomplicated peptic ulcer disease, history of peptic ulcer bleeding, and concomitant use of clopidogrel, ticlopidine, warfarin, nonsteroidal anti‐inflammatory drugs (NSAIDs), cyclooxygenase‐2 inhibitors, steroids, proton pump inhibitors (PPIs), histamine‐2 receptor antagonists (H2RAs), nitrates, alendronate, selective serotonin reuptake inhibitors (SSRIs) and calcium channel blockers. Results A total of 53 805 aspirin users and 269 025 controls were included. Aspirin group had a higher incidence of LGIB within 1 year than control group (0.20% vs 0.06%, P
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.14079